‘‘(1) IN
GENERAL.—There is established a 
SPRINT Award Program, under which the Sec-
retary may, in consultation or partnership with a 
nonprofit strategic investment entity, award con-
tracts, grants, cooperative agreements, or enter into 
other transactions, such as prize payments, to sup-
port advanced research and the development of 
therapies, in order to carry out paragraphs (4) and 
(6) of subsection (e). Awards granted through the 
SPRINT Award Program shall be funded by the 
SPRINT Program. 
‘‘(2) ELIGIBILITY; APPLICATION.— 
‘‘(A) ELIGIBILITY.—To be eligible to re-
ceive an award under this section, an entity 
shall be a public, nonprofit, early stage com-
pany, or growth company, which may include a 
private or public research institution, an insti-
tution of higher education, a medical center, a 
biotechnology company, a pharmaceutical com-
pany, a medical device company, an academic 
research institution, or other organization spe-
cializing in advanced research and development, 
and shall submit an application to the Secretary 
as described in subparagraph (B). 
VerDate Mar 15 2010 
20:20 Feb 03, 2012
Jkt 019200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H3891.IH
H3891
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(B) APPLICATION.—An entity desiring an 
award under this subsection shall submit to the 
Secretary an application at such time, in such 
manner, and containing such information as the 
Secretary may require, such as— 
‘‘(i) a detailed description of the 
project for which the entity seeks an 
award; 
‘‘(ii) a timetable for carrying out such 
project; 
‘‘(iii) an assurance that the entity will 
submit interim reports and a final report 
at the conclusion of the award period, as 
determined appropriate by the Secretary 
under paragraph (3); 
‘‘(iv) a description of how the project 
will lead to the development of therapies 
aimed at preventing, curing, reversing, or 
slowing the progression of an underlying 
chronic condition; and 
‘‘(v) a description of how the project 
will support efforts to reduce long-term 
Federal spending on health care. 
‘‘(3) AWARDEE REPORTING REQUIREMENTS.— 
An entity that receives an award under this sub-
VerDate Mar 15 2010 
20:20 Feb 03, 2012
Jkt 019200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H3891.IH
H3891
srobinson on DSK4SPTVN1PROD with BILLS
section shall submit reports to the Secretary which 
may include— 
‘‘(A) 
interim 
reports 
describing 
the 
progress in carrying out the project and compli-
ance with all conditions of receipt of such 
award; 
‘‘(B) a final report at the conclusion of the 
award period describing— 
‘‘(i) the outcomes of the project, in-
cluding whether the entity achieved the 
goals set forth in the application; 
‘‘(ii) the protocols the entity followed 
to carry out the research and comply with 
the research and ethical standards of the 
National Institutes of Health, if applicable; 
and 
‘‘(iii) the standards and regulatory re-
quirements of the Food and Drug Admin-
istration at all stages of development, man-
ufacturing, review, approval, and safety 
surveillance, if applicable; and 
‘‘(C) such additional information required 
by the Secretary. 
‘‘(4) TERMINATION
OF
FUNDING.—The Sec-
retary may modify or terminate a contract, grant, 
VerDate Mar 15 2010 
20:20 Feb 03, 2012
Jkt 019200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H3891.IH
H3891
srobinson on DSK4SPTVN1PROD with BILLS
cooperative agreement, other transaction, or prize to 
an awardee that does not meet milestones that are 
conditions of the contract, grant, cooperative agree-
ment, other transaction, or prize. 
‘‘(5) CONSULTATION
WITH
NONPROFIT
STRA-
TEGIC
INVESTMENT
ENTITY.—In making awards 
under this subsection, the Secretary may consult or 
partner with a nonprofit strategic investment entity 
or entities that— 
‘‘(A) operate independently of the Depart-
ment of Health and Human Services and con-
sist of experts in neurology, biomedical re-
search, drug and medical technology innovation 
and discovery, economics, and venture financ-
ing; and 
‘‘(B) have a record of— 
‘‘(i) promoting the development of 
therapies; and 
‘‘(ii) supporting novel technologies 
that have the potential to improve the de-
velopment of therapies. 
‘‘(6) MATCHING FUNDS.— 
‘‘(A) IN
GENERAL.—The Secretary may 
not make an award under this section unless 
the recipient involved agrees to make available 
VerDate Mar 15 2010 
20:20 Feb 03, 2012
Jkt 019200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H3891.IH
H3891
srobinson on DSK4SPTVN1PROD with BILLS
non-Federal contributions, in cash or in-kind, 
toward the costs of the project in an amount 
equal to not less than $2 for each $1 of Federal 
funds provided in the award. Such contributions 
may be made directly or through donations 
from public or private entities. Amounts pro-
vided by the Federal Government, or services 
assisted or subsidized to any significant extent 
by the Federal Government, may not be in-
cluded in determining the amount of such con-
tributions. 
‘‘(B) EXCEPTION.—The Secretary may 
waive or modify the matching requirement 
under subparagraph (A) on a case-by-case basis 
for each award if the Secretary determines that 
the goals and objectives of the SPRINT Award 
Program cannot adequately be carried out un-
less such requirement is waived. 
‘‘(g) NON-DUPLICATION
OF EFFORTS.—The Sec-
retary shall ensure that the activities under this section 
complement and extend other efforts of the Department 
of Health and Human Services. 
‘‘(h) GIFTS IN SUPPORT OF THE SPRINT AWARD 
PROGRAM.—The Secretary may accept on behalf of the 
United States money gifts and bequests made uncondi-
VerDate Mar 15 2010 
20:20 Feb 03, 2012
Jkt 019200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H3891.IH
H3891
srobinson on DSK4SPTVN1PROD with BILLS